Ariadne Genomics and Prolexys Partner to Deliver Advanced Pathway Analysis Tools for Pharmaceutical Research

Ariadne Genomics, Inc., and Prolexys Pharmaceuticals, Inc. announce a collaboration to deliver superior pathway analysis tools to boost pharmaceutical research related to target identification and novel therapeutic discovery. The Human Interactome Database (HID) by Prolexys will be integrated with Ariadne’s PathwayStudio® and PathwayExpert™, and available for purchasing with its pathway analysis software.

Rockville, MD (PRWEB) November 16, 2005 -- Ariadne Genomics, Inc., and Prolexys Pharmaceuticals, Inc. announce a collaboration to deliver superior pathway analysis tools to boost pharmaceutical research related to target identification and novel therapeutic discovery. The Human Interactome Database (HID) by Prolexys will be integrated with Ariadne’s PathwayStudio® and PathwayExpert™, and available for purchasing with its pathway analysis software.

Prolexys’ HID is an extensive, accurate collection of experimentally verified human protein-protein interactions (PPI). It is by far the largest human PPI database in the world, containing over 120,000 non-redundant interactions. Ariadne Genomics pathway visualization and analysis software allows biologists to identify relationships among genes, build molecular interaction networks, automatically extract biological interactions from scientific literature, and reconstruct pathways from microarray data.

“Integration of the Prolexys database with PathwayStudio and PathwayExpert will add value to pharmaceutical research in the areas of novel target identification, target validation, improved understanding of disease biology, and efficient choice of research direction,” commented Kimberly Rogers, Ph.D., Vice President of Business Development at Prolexys. “The addition of its powerful analytical tools along with strong visualization capability takes our database to a new level of usability.”

“Ariadne Genomics is striving to provide top of the line systems biology tools to the life science and pharma research community,” said Ilya Mazo, President of Ariadne Genomics. “Databases are a core part of pathway software. Our pathway analysis products include the ResNet database of 500,000+ interactions automatically extracted from the literature, but the availability of the HID experimentally proven data cannot be underestimated.”

The Prolexys database will be available from Ariadne Genomics' for an additional fee to its commercial customers. For more information, please visit www.ariadnegenomics.com, www.prolexys.com, or call 240-453-6296.

About Ariadne Genomics
Ariadne Genomics develops systems biology tools for life science research: PathwayStudio® Central client-server and PathwayAssist™ desktop pathway analysis software; MedScan™ Text-to-Knowledge Suite, an automated scientific text processing tool; ResNet™ molecular networks database, created by extraction of biological facts from the entire PubMed, and Seqware™ personal sequence data management platform. More on Ariadne Genomics please find at www.ariadnegenomics.com.

About Prolexys
Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs. The Company’s therapeutic focus is on cancer and asthma where Prolexys has identified novel therapeutic targets. Small molecules that act at these targets have been identified and tested in cell and animal models of disease. Lead programs include selective anti-tumor compounds and HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.

###